Fecal calprotectin is a protein that is found in the white blood cells present in the intestines. Elevated levels of fecal calprotectin are associated with gastrointestinal conditions such as inflammatory bowel disease (IBD). Fecal calprotectin tests help identify if acute or chronic inflammation is present in the intestines, thereby enabling diagnosis and monitoring the progression of IBDs such as ulcerative colitis and Crohn’s disease. The global market for fecal calprotectin testing has witnessed significant growth in recent years due to the rising prevalence of IBD worldwide. According to statistics, approximately 3 million people in the US and 2.5 million people in Europe suffer from IBD. The growing incidence of IBD due to factors such as genetic predisposition and changing lifestyle and dietary patterns is expected to drive the demand for fecal calprotectin testing over the forecast period.

The global Fecal Calprotectin Test Market is estimated to be valued at US$ 140.6 Million in 2024 and is expected to exhibit a CAGR Of 3.9% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

Technological advancements in fecal calprotectin testing is one of the key trends observed in the market. Traditionally, fecal calprotectin analysis involved time-consuming laboratory-based methods such as enzyme-linked immunosorbent assay (ELISA). However, newer rapid point-of-care tests that can provide quantitative fecal calprotectin results within 30 minutes are gaining popularity. Examples of such tests include Rapid fCAL turbo by Bühlmann laboratories and IBDoc FCAL immunoassay by Immundiagnostik. The availability of easy-to-use rapid tests is expected to increase the adoption of fecal calprotectin testing, thereby supporting the market growth over the forecast period.

Porter’s Analysis

Threat of new entrants: The threat of new entrants in the fecal calprotectin test market is low as it requires huge capital investments and R&D costs for developing new diagnostic tests.

Bargaining power of buyers: The bargaining power of buyers is moderate as the buyers have several established players to choose from for fecal calprotectin tests.

Bargaining power of suppliers: The bargaining power of suppliers is low as there are many suppliers for raw materials used in fecal calprotectin tests like antibodies and reagents.

Threat of new substitutes: The threat of new substitutes is low as there are limited substitution options for fecal calprotectin tests in determining inflammatory bowel disease.

Competitive rivalry: The competitive rivalry in the market is high due to the strong presence of many global as well as regional market players.

Key Takeaways

The Global Fecal Calprotectin Test Market Demand is expected to witness high growth over the forecast period owing to the rising prevalence of inflammatory bowel diseases. The global Fecal Calprotectin Test Market is estimated to be valued at US$ 140.6 million in 2024 and is expected to exhibit a CAGR of 3.9% over the forecast period 2023 to 2030.

North America is anticipated to hold a major market share owing to growing awareness about fecal calprotectin tests and rising inflammatory bowel disease cases in the region. Europe is projected to witness significant growth due to increasing adoption of advanced diagnostic procedures to detect underlying gastrointestinal diseases. Rising government initiatives to spread awareness about inflammatory bowel diseases and availability of technologically advanced POC diagnostic devices are expected to drive market growth in Europe.

Key players operating in the fecal calprotectin test market are Thermo Fisher Scientific, Inc., Nal von Minden GmbH, Aurora Diagnostics, BÜHLMANN Laboratories AG, Biomedex, Diagnostische Systeme und Technologien GmbH, Alpha Laboratories, Biohit Oyj, Arkray, Inc., and Tulip Diagnostics Ltd.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it